排序方式： 共有3条查询结果，搜索用时 0 毫秒
1
1.
Rani James K. Thriveni Girija Ramaswamy Lakshmi Krishnamoorthy Geetashree Mukherjee P. P. Vijayalaxmi Deshmane P. P. Bapsy 《Indian journal of clinical biochemistry : IJCB》2008,23(4):345-351
HER-2 is overexpressed in approximately 20–30% of invasive Breast Cancer. ECD of the HER-2 protein is frequently cleaved and
released into the circulation, where it can be detected by ELISA in up to 45% of patients with metastatic breast cancer. The
objective of our study was to compare the current methods for the detection of HER-2 protein. Tissue HER-2 levels were studied
in 100 breast cancer patients by IHC and compared with serum HER-2 levels by ELISA. IHC frequency was 29%. Serum HER-2 ECD
was positive in 42% of patients. A statistically significant correlation was observed. HER-2 detected by IHC correlates significantly
with serum HER-2 levels detected by ELISA. Thus, ELISA is a reliable and economical tool to assess the HER-2 status in tumors,
when breast tissue sample is not available. 相似文献
2.
K. Thriveni Lakshmi Krishnamoorthy Girija Ramaswamy 《Indian journal of clinical biochemistry : IJCB》2007,22(1):57-60
Carcino Embryonic Antigen (CEA) and Cancer Antigen 15.3 (CA15.3) are the most common tumor markers in breast cancer patients.
Measurement of circulating tumor markers is a non-invasive quantitative method. Serum levels of CEA and CA 15.3 were studied
in female breast cancer patients prior to treatment. To evaluate the utility of these markers, 207 Breast carcinoma patients
belonging to all the stages were considered. Healthy age matched 75 female individuals formed the control group. The serum
levels of CEA and CA 15.3 were analyzed by Enzyme Linked Immunosorbent Assay (ELISA). Results were taken and compared with
stages, tumor size, node and grade. The serum CA 15.3 levels were significant in all the study parameters whereas serum CEA
levels showed no significant changes with any of the parameters. Measurement of serum CA 15.3 levels showed significant correlation
(24.8%) with advanced stages and larger tumor sizes, whereas serum CEA levels did not show any significant correlation in
breast cancer patients prior to treatment. 相似文献
3.
Karuvaje Thriveni Vijayalaxmi Deshmane Girija Ramaswamy Lakshmi Krishnamoorthy 《Indian journal of clinical biochemistry : IJCB》2013,28(2):136-140
The human epidermal receptor-2/neu (HER-2/neu) oncogene encodes a transmembrane tyrosine kinase receptor. This molecule could have a diagnostic value since the extracellular domain of c-erbB-2 (HER-2) transmembrane is shed into the blood as a circulating antigen. The diagnostic value of serum HER-2/neu was calculated along with the conventional marker carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) at 85th percentiles. Serum levels of breast carcinoma antigens HER-2/neu, CEA and CA15-3 were determined in 175 normal individuals and 268 malignant patients. The soluble form of serum HER-2/neu, CEA and CA15-3 was assayed by enzyme linked immunosorbent assay in control and breast cancer patients prior to treatment. Serum levels of the tested tumor markers HER-2/neu and CA15-3 and CEA were significantly higher in cancer patients compared to controls. At 85th percentile the sensitivity of HER-2/neu was 51.12 %; the specificity was 86.29 % and the overall accuracy was 64.56 %. The sensitivity of CA15-3 was 73.13 %; the specificity was 85.14 % and the overall accuracy was 77.88 %. The sensitivity of the combined testing was 82.84 %; the specificity was 73.71 % and the overall accuracy was 80.01 %. The sensitivity and the overall accuracy of combined testing were higher than those of HER-2/neu and CA15-3 testing single. The combined testing of HER-2/neu and CA15-3 can increase the sensitivity and overall accuracy of breast cancer diagnosis. The results of this study suggest that the use of multiple tumor markers may be employed as combination and at 85th percentiles to assess the prognosis. 相似文献
1